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Abstract: Objective: To perform a dose–response meta-analysis of prospective cohort studies investigating
the association between long-term coffee intake and risk of hypertension. Methods: An online systematic
search of studies published up to November 2016 was performed. Linear and non-linear dose–response
meta-analyses were conducted; potential evidence of heterogeneity, publication bias, and confounding
effect of selected variables were investigated through sensitivity and meta-regression analyses.
Results: Seven cohorts including 205,349 individuals and 44,120 cases of hypertension were included.
In the non-linear analysis, there was a 9% significant decreased risk of hypertension per seven cups of
coffee a day, while, in the linear dose–response association, there was a 1% decreased risk of hypertension
for each additional cup of coffee per day. Among subgroups, there were significant inverse associations for
females, caffeinated coffee, and studies conducted in the US with longer follow-up. Analysis of potential
confounders revealed that smoking-related variables weakened the strength of association between coffee
consumption and risk of hypertension. Conclusions: Increased coffee consumption is associated with
a modest decrease in risk of hypertension in prospective cohort studies. Smoking status is a potential
effect modifier on the association between coffee consumption and risk of hypertension.
Keywords: coffee; hypertension; risk; cohort; smoking; meta-analysis
1. Introduction
Coffee has been the focus of major attention due to its global consumption and impact on health [1].
Historically, coffee consumption was considered to have detrimental effects on health, particularly its
contribution to high blood pressure [2]. However, coffee contains many other bioactive compounds,
such as polyphenols, furans, pyrroles, and maltol, all of which have recently been hypothesized to
have potential beneficial effects on human health [3,4]. Meta-analyses of prospective cohort studies
show a J-shaped dose–response relationship between coffee consumption and decreased risk of
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cardiovascular disease (CVD), including coronary heart disease and stroke [5], and mortality [6]
suggesting that moderate consumption is key for its beneficial effects. Studies exploring acute events
most likely triggered by coffee-dependent increase in blood pressure showed no substantial increase in
mortality due to myocardial infarction [7] and atrial fibrillation [8]. Apart from cardiovascular health,
coffee consumption has been hypothesized to affect a number of other conditions, including metabolic
status [6] and risk of late-life cognitive impairment [9,10].
Overall, the benefits of coffee on human health seem evident; however, the association
between coffee consumption and in particular risk of hypertension remains open for debate.
Results from meta-analyses of randomized controlled trials testing the effects of caffeine intake and
decaffeinated coffee on blood pressure were null and showed no increase in blood pressure [11,12];
however, these studies simply evaluated the effect of the caffeine in coffee and not of coffee itself.
Due to the relatively short-term follow-up, previous studies mostly emphasized the acute effects of
coffee intake rather than its long-term effects on blood pressure. Two previous meta-analyses of
prospective cohort studies [13,14] reported non-significant increased risk of hypertension associated
with higher intake of coffee. However, those meta-analyses only included a few studies reporting
dose–response analysis and did not correct for the number of individuals/cases/person-years,
and potential confounding factors/effect modifiers, ultimately providing limited-quality evidence.
In light of these limitations and the availability of newly published cohort studies, this study aims to
conduct a dose–response meta-analysis of prospective cohort studies investigating coffee consumption
and the risk of hypertension.
2. Materials and Methods
The design, analysis, and reporting of this study is compliant with the Preferred Reporting Items
for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (Table S1).
2.1. Study Selection
A systematic search of PubMed (http://www.ncbi.nlm.nih.gov/pubmed/) and EMBASE (http:
//www.embase.com/) databases was conducted for studies up to November 2016 using the following
search strategy: (“coffee” (MeSH Terms) OR “coffee” (All Fields)) AND (“hypertension” (MeSH Terms)
OR “hypertension” (All Fields)) AND (cohort (All Fields) OR (“longitudinal studies” (MeSH Terms)
OR (“longitudinal” (All Fields) AND “studies” (All Fields)) OR “longitudinal studies” (All Fields)
OR “prospective” (All Fields) OR cases (All Fields). The inclusion criteria consisted of studies that:
(i) are prospective; (ii) evaluated the association of coffee intake and the risk of hypertension in
individuals without hypertension at baseline; (iii) assessed and reported hazard ratios (HRs), risk ratios
(RRs), or odds ratios (ORs) and 95% CI for hypertension; and (iv) assessed and reported a defined
amount of coffee consumption (i.e., cups per day) for each category of exposure. Reference lists of the
included studies were also searched for any additional study not previously identified. For papers that
studied the same cohort, only the study that included the entire cohort or had the longest follow-up
was included.
2.2. Data Extraction
Data were extracted by two independent investigators (G.G. and A.M.) using a standardized
extraction form. Discrepancies on the included studies were discussed and resolved by consensus.
The following information was collected: (i) first author name; (ii) year of publication; (iii) study cohort
name and country; (iv) total number, sex, and age (mean or range) of participants; (v) follow-up period;
(vi) distributions of cases and person-years, HRs/RRs/ORs and 95% CIs for all categories of exposure;
(vii) coffee intake range for each category of exposure; (viii) adjusted covariates; (ix) prevalence of
smokers, diabetic subjects, and participants with low physical activity for each category of exposure;
and (x) baseline mean/median systolic and diastolic blood pressure, age, body mass index (BMI),
and daily intake of sodium and potassium for each category of coffee intake.
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2.3. Study Quality Assessment
The quality of each study was assessed according to the Newcastle-Ottawa Quality Assessment
Scale [15] composed of 3 variables: selection (4 points), comparability (2 points), and outcome (3 points)
resulting in a total score of 9 points (9 representing the highest quality). Studies scoring 7–9 points,
3–6 points, and 0–3 points were identified as high, moderate, and low quality, respectively.
2.4. Statistical Analysis
In this meta-analysis, ORs and HRs referring to new onset incident cases of hypertension were
deemed equivalent to risk ratios (RRs) [16]. When coffee consumption was illustrated by ranges of
intake, the midpoint of the range was used. When the highest category was open-ended, we assumed
that the width of the upper category was the same as the adjacent category. When the lowest category
was open-ended, we set the lower boundary to zero. Two-stage random-effects dose–response
meta-analysis was performed to examine linear and non-linear relationship between coffee intake and
risk of developing hypertension during follow-up.
First, generalized least-squares (GLS) were used to calculate study-specific coefficients across categories
of coffee intake accounting for the correlation within each set of RRs [17,18]. Non-linear dose–response
analysis was modeled using restricted cubic splines with 3 knots at fixed percentiles (25%, 50%,
and 75%) of the distribution [19]. Coefficients estimated within each study were combined by
performing random-effects meta-analysis. DerSimonian and Laird’s method was used for linear
dose–response meta-analysis and, in non-linear dose–response meta-analysis, the multivariate
extension of the method of moments was used to estimate the RRs. We tested whether the 2 regression
coefficients were simultaneously equal to zero and calculated a p-value for non-linearity by testing
whether the coefficient of the second spline was equal to zero. A sensitivity analysis by excluding one
study at the time was conducted to determine the stability and robustness of the results.
To test for potential confounders, subgroup analyses by sex, type of coffee, and geographical
area were performed. To further investigate whether other unmeasured potential confounders should
be included in the interpretation of the results, we investigated the distribution of systolic blood
pressure, diastolic blood pressure, age, BMI, daily intake of sodium and potassium, percentage of
smokers, participants with low physical activity and those with type-2 diabetes across categories of
coffee consumption. For this purpose, a separate two-stage bivariate meta-analysis was performed for
each confounder variable to determine its association with coffee intake [20]. First, linear regression
coefficients (slope and intercept) between coffee intake and the potential confounders above were
estimated. Second, we used GLS to synthesize these intercepts and slope coefficients, accounting for
the corresponding variance-covariance matrices [21]. To determine the significance of the proposed
confounders on the association of coffee consumption and risk of hypertension, a meta-regression
analysis was conducted. Specifically, we used the joint slope coefficient of the association as the
moderator in the meta-regression analysis. Percentage of smokers was also used as moderator.
Publication bias was assessed using Egger’s regression test while the Cochran Q-test tested for
statistical heterogeneity (statistical significance is defined as a p value less than 0.10) and quantified
through the multivariate generalization of the I2 statistic (no, low, medium, and high heterogeneity
were defined by I2 values <25%, 25–50%, 50–75%, and >75%, respectively). All analyses were performed
on R, software version 3.0.3, dosresmeta and mvmeta packages (Development Core Team, Vienna, Austria).
3. Results
3.1. Study Characteristics
The selection process of studies included in the meta-analysis is illustrated in Figure 1. Out of the
139 studies screened, six studies [22–27] involving seven cohorts, 205,349 individuals, and 44,120 cases of
hypertension were included (Table 1). The sample of three studies included general population [24–26],
registered US nurses (2 cohorts) [23], post-menopausal women [27], and post-graduate students [22].
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Four cohorts were based in the US [22,23,27] and three in Europe [24–26]. Sex-specific (both male and
female) risk estimates were provided by three studies [24–26], while two papers [23,27] studied only
females and one only males [22]. Follow-up periods ranged an average of 3–33 years. All studies adjusted
for variables that affect the risk of hypertension, including age, gender, BMI, and smoking status. Overall,
the quality of all included studies was high (data not shown).
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Table 1. Main characteristics of prospective cohort studies investigating the association of coffee consumption and risk of hypertension.
Author, Year Name of Cohort (Yearsof Recruitment), Country Cohort Size No. of Cases Gender Exposure Variables
Follow-Up
Duration Adjusted Variables
Grosso, 2016 (21) HAPIEE Cohort Study(2002–2008), Poland 2725 1735 MF
Caffeinated and
decaffeinated coffee 5 y
Age, gender, education, occupation, BMI, alcohol
consumption, smoking status, physical activity level,
past history of CVD and diabetes at baseline,
cholesterol therapy at baseline, total energy intake,
vitamin supplement use, oral contraceptive use, and
intake of sodium and potassium.
Rhee, 2016 (22) WHI Observational Study,(1993), US 29,985 5566 F Caffeinated coffee 3 y
Age, baseline blood pressure, BMI, physical activity,
hormone replacement therapy, alcohol consumption,
smoking status, total calorie intake, and intake of
sodium, magnesium, calcium, potassium, and
phosphorus as time-varying covariates.
Uiterwaal, 2007 (20) DCS (1987–2002),The Netherlands 6368 956 MF
Caffeinated and
decaffeinated coffee 11 y
Baseline age, sex, height and weight, smoking, alcohol
intake, tea intake, education level, occupational status,





24,710 2505 MF Caffeinated anddecaffeinated coffee 13.2 y
Year, education, leisure-time physical activity,
smoking status, alcohol consumption, tea
consumption, frequency of vegetable, fruit, sausage,
and bread consumption, BMI, history of diabetes and
total cholesterol, and baseline systolic blood pressure.
Winkelmayer, 2005 (18) NHS I (1976–2002), US 53,175 19,541 F Caffeinated coffee 12 y
Age, BMI, alcohol consumption, family history of
hypertension, physical activity, and smoking status,
and intake of other beverages.
Winkelmayer, 2005 (18) NHS II (1989–2003), US 87,369 13,536 F Caffeinated coffee 12 y
Age, BMI, alcohol consumption, family history of
hypertension, oral contraceptive use, physical activity,
and smoking status, and intake of other beverages.
Klag, 2002 (17) JHPS (1947–1995), US 1017 281 M Caffeinated coffee 33 y
Parental history of hypertension, time-dependent
number of cigarettes smoked, alcohol intake, physical
activity, BMI.
DCS: Doetinchem Cohort Study; HAPIEE: Health, Alcohol and Psychosocial factors In Eastern Europe; JHPS: John Hopkins Precursors Study; NHS: Nurses’ Health Study; WHI: Women’s
Health Initiative Observational Study; y: year.
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3.2. Coffee Consumption and Risk of Hypertension
The dose–response regression in Figure 2A illustrates a non-significant decrease in risk of
hypertension with up to six cups/day and a 9% significant decrease in risk observed for seven
cups/day (RR = 0.91, 95% CI: 0.83–1.00), with moderate evidence of heterogeneity (I2 = 51%,
Pheterogeneity = 0.004) and no publication bias (PEgger = 0.755) (Table 2). After exclusion of one study [24],
the association between coffee consumption and risk of hypertension became significant with no
evidence of heterogeneity and publication bias (Table S2). When linear dose–response regression
(test for non-linearity resulted not significant) was modeled, similar risk estimates resulted (Figure 2B),
where there was a 1% decreased risk of hypertension with each additional cup of coffee per day
(RR = 0.99, 95% CI: 0.98, 1.00; I2 = 21%, Pheterogeneity = 0.241; Figure 3). Stratified analyses by sex,
geographical area, type of coffee consumed, and length of follow-up were limited by the small number
of datasets; however, significant inverse associations were observed in studies conducted in the US,
and those that studied only females, caffeinated coffee, and had longer follow-up (Table 2).
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Table 2. Dose–response meta-analysis of coffee consumption and risk of hypertension, stratified by selected variables.
No. of Datasets (No. of Studies)
Coffee Intake (Cups/Day)
I2 Pheterogeneity
0 1 2 3 4 5 6 7
All
Non-linear 10 (6) Ref. 1.01 (0.98–1.03) 1.01 (0.97–1.06) 1.01 (0.95–1.07) 0.98 (0.92–1.05) 0.96 (0.89–1.03) 0.93 (0.86–1.01) 0.91 (0.83–1.00) 51% 0.004
Linear 10 (6) Ref. 0.99 (0.98–1.00) 0.98 (0.96–0.99) 0.97 (0.94–0.99) 0.96 (0.92–0.99) 0.95 (0.91–0.99) 0.94 (0.89–0.98) 0.92 (0.87–0.98) 21% 0.241
Males
Non-linear 3 (3) Ref. 1.09 (0.94–1.27) 1.19 (0.89–1.58) 1.24 (0.88–1.76) 1.23 (0.89–1.69) 1.19 (0.9–1.59) 1.16 (0.86–1.55) 1.12 (0.79–1.59) 0% 0.458
Linear 3 (3) Ref. 1.02 (0.98–1.06) 1.04 (0.95–1.13) 1.06 (0.93–1.21) 1.08 (0.91–1.28) 1.1 (0.89–1.36) 1.12 (0.86–1.45) 1.14 (0.84–1.55) 0% 0.458
Females
Non-linear 4 (4) Ref. 1.00 (0.97–1.03) 1.00 (0.94–1.05) 0.98 (0.92–1.04) 0.95 (0.91–0.99) 0.92 (0.88–0.95) 0.88 (0.84–0.94) 0.85 (0.78–0.93) 43% 0.059
Linear 6 (4) Ref. 0.99 (0.98–0.99) 0.97 (0.95–0.99) 0.96 (0.93–0.98) 0.94 (0.91–0.98) 0.93 (0.89–0.97) 0.92 (0.87–0.97) 0.90 (0.85–0.96) 26% 0.232
Caffeinated coffee
Non-linear 4 (3) Ref. 1.00 (0.97–1.02) 0.99 (0.95–1.04) 0.98 (0.93–1.03) 0.95 (0.92–0.99) 0.92 (0.89–0.96) 0.9 (0.84–0.96) 0.87 (0.79–0.96) 44% 0.095
Linear 4 (3) Ref. 0.98 (0.98–0.99) 0.97 (0.95–0.98) 0.95 (0.93–0.98) 0.94 (0.91–0.97) 0.92 (0.89–0.96) 0.91 (0.87–0.95) 0.9 (0.85–0.94) 0% 0.529
Europe
Non-linear 5 (3) Ref. 1.02 (0.9–1.16) 1.04 (0.81–1.33) 1.06 (0.76–1.48) 1.08 (0.8–1.47) 1.12 (0.92–1.35) 1.15 (0.98–1.35) 1.19 (0.91–1.55) 54% 0.025
Linear 5 (3) Ref. 0.99 (0.96–1.02) 0.97 (0.91–1.04) 0.96 (0.87–1.05) 0.95 (0.83–1.07) 0.93 (0.79–1.09) 0.92 (0.76–1.11) 0.91 (0.72–1.13) 38% 0.166
US
Non-linear 3 (3) Ref. 1 (0.98–1.02) 1 (0.96–1.04) 0.98 (0.94–1.03) 0.96 (0.92–0.99) 0.92 (0.89–0.96) 0.89 (0.84–0.94) 0.86 (0.79–0.93) 36 0.130
Linear 5 (3) Ref. 0.99 (0.98–0.99) 0.97 (0.96–0.99) 0.96 (0.94–0.98) 0.95 (0.92–0.97) 0.93 (0.9–0.97) 0.92 (0.88–0.96) 0.91 (0.86–0.95) 1% 0.398
Follow up >10 years
Non-linear 6 (4) Ref. 1.02 (0.99–1.04) 1.03 (0.98–1.09) 1.02 (0.96–1.10) 0.99 (0.91–1.08) 0.95 (0.85–1.05) 0.91 (0.79–1.03) 0.87 (0.74–1.01) 57% 0.01
Linear 6 (4) Ref. 0.99 (0.98–1.00) 0.97 (0.96–0.99) 0.96 (0.93–0.99) 0.95 (0.91–0.99) 0.94 (0.89–0.98) 0.93 (0.87–0.98) 0.91 (0.85–0.98) 21% 0.277
Follow up <10 years
Non-linear 4 (2) Ref. 0.97 (0.91–1.04) 0.95 (0.85–1.07) 0.94 (0.83–1.07) 0.94 (0.83–1.07) 0.95 (0.83–1.08) 0.95 (0.82–1.1) 0.95 (0.80–1.12) 43% 0.101
Linear 4 (2) Ref. 0.99 (0.97–1.01) 0.98 (0.94–1.02) 0.97 (0.92–1.04) 0.97 (0.89–1.05) 0.96 (0.86–1.06) 0.95 (0.84–1.07) 0.94 (0.82–1.09) 31% 0.225
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3.3. Potential Confounding Factors
The distribution of systolic and diastolic blood pressure and percentage of smokers across
categories of coffee consumption was explored in four studies where a significant association was
evident only with diastolic blood pressure (Figure 4). The prevalence of smokers in the no-coffee
consumption category was 16.8%, which increased by about 6.4% for each additional cup of coffee
consumed per day (Table 3).
Figure 5 illustrates two meta-regression models to test the confounding role of smoking status on
the association of coffee consumption and risk of hypertension, both of which resulted in insignificant
associations. With prevalence of smokers as the moderator (Figure 5A), studies with lower prevalence
showed that coffee consumption was associated with decreased risk of hypertension, while in studies
with higher prevalence, coffee consumption was associated with increased risk. With slope coefficients
as the moderator (Figure 5B), studies with no change in prevalence of smokers across categories
of coffee consumption (lower slope values) showed that coffee consumption was associated with
decreased risk of hypertension, while, in studies where increased coffee consumption was linearly
associated with higher prevalence of smokers (higher slope values), coffee consumption was associated
with increased risk of hypertension.
Nutrients 2017, 9, 890 8 of 13 
 
3.3. Potential Confounding Factors 
The distribution of systolic and diastolic blood pressure and percentage of smokers across 
categories of coffee consumpti n was explored n four studies where a significant association was 
evident only with diastolic blood pressure (Figure 4). The prevalence of smokers in the no-coffee 
consumption category was 16.8%, which increased by about 6.4% for each additional cup of coffee 
consumed per day (Table 3). 
Figure 5 illustrates two meta-regression models to test the confounding role of smoking status 
on the association of coffee consumption and risk of hypertension, both of which resulted in 
insignificant associations. With prevalence of smokers as the moderator (Figure 5A), studies with 
lower prevalence showed that coffee consumption was associated with decreased risk of 
hypertension, while in studies with higher prevalence, coffee consumption was associated with 
increase  risk. With slope coefficients as t e moderator (Figur  5B), studie  with no change in 
prevalence of smokers across categories of coffee consump ion (lower slope values) showed that 
coffee consumption was ass ciated with decreased risk of hypertension, while, in studies where 
increased coffee consumption was linearly associated with higher prevalence of smokers (higher 
slope values), coffee consumption was associated with increased risk of hypertension. 
 
Figure 4. Scatter plots illustrating the relationship between coffee consumption (in cups per day) and 
baseline characteristics in the prospective cohorts: (A) systolic blood pressure; (B) diastolic blood 
pressure; (C) percentage of smokers; (D) percentage of low physically active individuals; (E) age; (F) 
percentage of diabetic individuals; (G) body mass index; (H) sodium intake; and (I) potassium 
intake. Symbols represent different cohorts; light lines represent linear regression coefficients of 
Figure 4. Scatter plots illustrating the relationship between coffee consumption (in cups per day) and
baseline characteristics in the prospective cohorts: (A) systolic blood pressure; (B) diastolic blood
pressure; (C) erce tage of smokers; (D) percentage of low physically active individuals; (E) age;
(F) percentage of diabetic individuals; (G) body mass index; (H) sodium intake; and (I) potassium
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increase in coffee intake. Cups/d: cups/day.
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Figure 5. Risk of hypertension for linear increase of coffee consumption and selected smoking-related
moderators: (A) total prevalence of smokers in the included cohorts; and (B) slope coefficients of the
association between coffee intake and percentage of smokers in each category of exposure and random
effects meta-regression. The area of each circle is inversely proportional to the variance of the log risk
ratio estimate; continuous lines represent average risk ratios; and dashed lines represent corresponding
95% confidence intervals.
Table 3. Summary of the associations between coffee consumption and selected variables.
No. of Datasets
(No. of Studies) Intercept (9 % CI) Slope per 1 Cup/Day (95% CI) p for Slope
SBP (mmHg) 5 (4) 122.3 (115.2, 129.3) 0.01 (−0.12, 0.13) 0.9345
DBP (mmHg) 5 (4) 75.6 (71.2, 79.8) −0.01 (−0.14, 0.12) 0.9131
Smokers (%) 5 (4) 16.9 (7.2, 26.7) 6.49 (3.77, 9.22) <0.001
BMI 5 (4) 25.4 (24.1, 26.6) 0.02 (−0.08, 0.13) 0.6461
Age (year) 5 (4) 48.9 (35.9, 61.8) −0.13 (−0.42, 0.15) 0.3565
Sodium (mg/day) 3 (2) 2903.2 (2480.9, 3325.6) 69.2 (37.0, 101.4) <0.001
Potassium (mg/day) 3 (2) 3326.6 (2613.5, 4039.7) 38.0 (3.2, 72.8) 0.0326
Low PA (%) 3 (2) 26.6 (23.8, 29.4) 0.38 (−0.83, 1.59) 0.5391
Diabetic (%) 3 (2) 4.48 (0.51, 8.45) −0.81 (−1.84, 0.22) 0.1218
BMI: body mass index; DBP: diastolic blood pressure; PA: physical activity; SBP: systolic blood pressure.
4. Discussion
This meta-analysis illustrated a linear association between increasing intake of coffee consumption
and decreased risk of hypertension in six prospective cohort studies. However, when smoking status
was included as a moderator in the meta-regression analyses, the association was weakened, suggesting
that smoking may be an effect modifier. Compared to previous meta-analyses [13,14], this study
included a larger sample (39,078 additional individuals and 8257 additional cases), dose–response
analyses, and tested for potential confounders. The comparison of differ nt ca eg ries of exposure
(i.e., the variation of cof ee intake across studies), may have biased the pooled risk estimates of previous
meta-analyses of cohort studies. Differences in the results from this study compared to those from
meta-analyses of randomized controlled trials [11,12] may be due to the potential long-term effect of
coffee consumption captured only in cohort studies.
From the subgroup analyses, this study showed significant results in studies (or datasets) that
only included women, were conducted in the US, and had a longer follow-up. Significant results seen
in women and not in men could be attributed to increased prevalence of smoking in males accounting
for 30% of all mortality in males 50–70 years [28]. To account for geographical differences in the
results, the number of participants in US cohorts was three times more than the European cohorts.
Thus, it can be inferred the number of individuals in the European cohorts was not large enough to
obtain the expected effect size. This is in fact in line with the results obtained, as risk estimates in
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both subgroups (US and European cohorts) were similar but the analysis of the European cohorts
had larger confidence intervals. Furthermore, significant results seen in studies with longer follow-up
seems intuitive since studies with longer follow-up more likely capture potential cases of chronic
non-communicable disease.
Apart from those above, other reasons may account for the differences observed between
subgroups (especially those between geographical areas), including variations in preferred coffee
constituents, variations in brewing and in the actual amount of coffee contained in “a cup” across
regions, and differences in population genetics. There is evidence that genetic factors related to target
receptors and CYP1A2, such as the genetic polymorphism rs762551, also known as −136 C>A CYP1A2,
encoding the CYP1A2*1F allele of the CYP1A2 gene, leads to slow metabolism of caffeine [29,30].
Carriers of the CYP1A2*1F allele have been demonstrated to be at higher risk of nonfatal myocardial
infarction following intake of caffeinated coffee [31]. Similarly, the risk of sustained hypertension has
been associated with CYP1A2*1F polymorphisms in a cohort of stage I hypertensive individuals [32].
Due to the variability of genetic polymorphisms of CYP1A2 enzyme, also related to ethnicity,
it is plausible that there exist such genetic polymorphisms in the examined cohorts that result in
the heterogeneity of our results, especially those found across geographical regions.
Another finding of this study was the potential effect modification of sodium intake on risk of
hypertension associated with coffee consumption. Despite insufficient data for further examining
this issue, three studies showed direct association between sodium intake and coffee consumption
where increased intake of one cup of coffee per day was associated with 38 mg/day additional
intake of sodium. It is known that increased sodium intake may be associated with increased fluid
retention, but does not increase urine volume excretion, thus leading to a rise in body weight and
blood pressure [33]. A comprehensive systematic review exploring data from 93 studies including
more than 600 empirically-derived dietary patterns reported that coffee was part of a “healthy” dietary
pattern in 4 studies and part of an “unhealthy” dietary pattern in 11 studies, suggesting that coffee
drinkers may have, at least in part, unhealthier dietary choices, which may include higher sodium
intake [34]. However, it is unclear whether the reported increase in sodium intake may have clinical
relevance and more studies are needed to better explore this potential association.
The biological evidence supporting the association between coffee consumption and decreased
risk of hypertension discounting caffeine intake has been investigated only during the last decade.
The coffee content in phenolic compounds has been considered the main factor responsible for the
beneficial effects on blood pressure mentioned previously [2]. The most studied compounds are
chlorogenic acids, including metabolites ferulic acid, caffeic acid and quinic acid, which have all been
reported to exert anti-hypertensive effects in experimental studies [35]. The main mechanisms of
action rely on the anti-oxidant activity of chlorogenic acid, through its inhibition of the NAD(P)H
oxidase expression and activity and by directly scavenging for free radicals [36]. Moreover, chlorogenic
acid has been reported to stimulate nitric oxide production by the endothelial-dependent pathway,
suggesting that vascular integrity, in particular, intact endothelium, is essential for chlorogenic acids to
have a blood pressure lowering effect [37,38].
This meta-analysis has some limitations that should be addressed. The main issue in interpreting
our findings depends on the potential confounders (smoking status, sodium intake) and genetic
polymorphisms that are not explored in existing cohorts. We attempted an in-depth analysis on the role
of smoking status, suggesting that it poses as an effect modifier. No data on genetic polymorphisms and
only limited data on sodium intake were available and, hence, we were not able to analyze the potential
effect modification of these variables, which may have weakened the observed results. Nevertheless,
the large number of individuals included, the lack of evidence on heterogeneity, and the observed
significant inverse association observed for the main effect variables all support the robustness of the
findings. Another limitation in the papers included in this study is the lack of information on the
type of coffee used (e.g., boiled, filtered, etc.) and on the actual amount of coffee used in one cup.
The type of coffee consumed by US cohorts could be different from those consumed by European
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cohorts, which contribute to the heterogeneous findings. Similarly, the amount of coffee added in
a cup can vary across countries. One cup of coffee could refer to 150 mL or 300 mL which is another
source of heterogeneity in these results. However, a previous meta-analysis that adjusted for the
varying measurements of coffee showed identical results to the unadjusted measures on the outcome
investigated [6].
Considering that the results from this meta-analysis may not account for the genetic variations
contributing to the slow metabolism of caffeine, overall current evidence suggest that usual coffee
consumption in the long-term is not a risk factor for developing hypertension in existing cohort
studies. Rather results show an inverse association of increase coffee consumption and the risk of
developing hypertension. Due to lack of long-term randomized controlled trials, results from cohort
studies represent the most reliable available evidence when studying long-term effects of food on
future health.
To date, our study provides a robust overview of the highest level of evidence that currently exists
on the association of coffee consumption and risk of hypertension. Nevertheless, more cohort studies
are needed to provide more in-depth and long-term evidence of this association. Additional factors
such as smoking status, sodium intake and genetic polymorphisms need to be addressed in future
studies to allow for stratified sub-group analyses. Further evidence on decaffeinated coffee could also
provide information on the role of caffeine in such long-term outcomes.
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